Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome

Airway nitric oxide concentrations in patients with cystic fibrosis or primary ciliary dyskinesia syndrome have been shown to be lower than in healthy subjects. Decreased NO concentrations may contribute to impaired ciliary clearance, respiratory tract infections, or obstructive lung disease in these conditions. Nasal and exhaled NO concentrations were compared before and after infusion of 500 mg x kg(-1) L-arginine, the substrate of NO synthases, in 11 cystic fibrosis (CF) patients, seven primary ciliary dyskinesia (PCD) syndrome patients, and 11 control subjects. Baseline nasal and exhaled NO concentrations were significantly lower in both CF and PCD syndrome patients than in controls (p<0.01). In controls, the maximum increase of NO was seen immediately after L-arginine infusion in the upper airways (1.8-fold) and 3 h after the infusion in the lower airways (1.4-fold). Although NO concentrations also increased significantly in both CF (1.9-fold and 1.6-fold, respectively) and PCD syndrome patients (1.4-fold and 1.8-fold, respectively), concentrations remained subnormal compared with baseline values of controls. Pulmonary function remained unchanged in both patient groups. In conclusion, the low airway nitric oxide formation in both cystic fibrosis and primary ciliary dyskinesia syndrome patients can be augmented by L-arginine administration. The finding that pulmonary function remained unchanged in both conditions may be due to the fact that normalization of airway nitric oxide concentrations could not be achieved.

This article has been cited by other articles:

				C. Grasemann, F. Ratjen, D. Schnabel, E. Reutershahn, U. Vester, and H. Grasemann Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients Eur. Respir. J., April 1, 2008; 31(4): 815 - 821. [Abstract] [Full Text] [PDF]

				D R Taylor, M W Pijnenburg, A D Smith, and J C D Jongste Exhaled nitric oxide measurements: clinical application and interpretation Thorax, September 1, 2006; 61(9): 817 - 827. [Abstract] [Full Text] [PDF]

				H. Grasemann, F. Kurtz, and F. Ratjen Inhaled L-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 208 - 212. [Abstract] [Full Text] [PDF]

				G. Borriello, L. Richards, G. D. Ehrlich, and P. S. Stewart Arginine or Nitrate Enhances Antibiotic Susceptibility of Pseudomonas aeruginosa in Biofilms Antimicrob. Agents Chemother., January 1, 2006; 50(1): 382 - 384. [Abstract] [Full Text] [PDF]

				V. M. D. Struben, M. H. Wieringa, C. J. Mantingh, C. Bommelje, M. Don, L. Feenstra, and J. C. de Jongste Nasal NO: normal values in children age 6 through to 17 years Eur. Respir. J., September 1, 2005; 26(3): 453 - 457. [Abstract] [Full Text] [PDF]

				ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005 Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 912 - 930. [Full Text] [PDF]

				H. Grasemann, C. Grasemann, F. Kurtz, G. Tietze-Schillings, U. Vester, and F. Ratjen Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study Eur. Respir. J., January 1, 2005; 25(1): 62 - 68. [Abstract] [Full Text] [PDF]

				E. Baraldi, M.F. Pasquale, A.M. Cangiotti, S. Zanconato, and F. Zacchello Nasal nitric oxide is low early in life: case study of two infants with primary ciliary dyskinesia Eur. Respir. J., November 1, 2004; 24(5): 881 - 883. [Abstract] [Full Text] [PDF]

				H. Grasemann, K. S. van's Gravesande, R. Buscher, N. Knauer, E. S. Silverman, L. J. Palmer, J. M. Drazen, and F. Ratjen Endothelial Nitric Oxide Synthase Variants in Cystic Fibrosis Lung Disease Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 390 - 394. [Abstract] [Full Text] [PDF]

				T. Wodehouse, S.A. Kharitonov, I.S. Mackay, P.J. Barnes, R. Wilson, and P.J. Cole Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia Eur. Respir. J., January 1, 2003; 21(1): 43 - 47. [Abstract] [Full Text] [PDF]

				Members of the Task Force:, E. Baraldi, J.C. de Jongste, B. Gaston, K. Alving, P.J. Barnes, H. Bisgaard, A. Bush, C. Gaultier, H. Grasemann, et al. Measurement of exhaled nitric oxide in children, 2001: E. Baraldi and J.C. de Jongste on behalf of the Task Force Eur. Respir. J., July 1, 2002; 20(1): 223 - 237. [Abstract] [Full Text] [PDF]

				H. GRASEMANN, N. KNAUER, R. BÜSCHER, K. HÜBNER, J. M. DRAZEN, and F. RATJEN Airway Nitric Oxide Levels in Cystic Fibrosis Patients Are Related to a Polymorphism in the Neuronal Nitric Oxide Synthase Gene Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2172 - 2176. [Abstract] [Full Text]

				H. NAKANO, H. IDE, M. IMADA, S. OSANAI, T. TAKAHASHI, K. KIKUCHI, and J. IWAMOTO Reduced Nasal Nitric Oxide in Diffuse Panbronchiolitis Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2218 - 2220. [Abstract] [Full Text]